Locomotive Syndrome Digital Therapeutics Provided via a Smartphone App: Proof-of-Concept Single-Group Trial Study
JMIR Aging · 2026
DOI: 10.2196/86174 ↗At a glance
Journal article in JMIR Aging, 2026. Written by Tatsuru Sonobe and 10 co-authors. Institution: Department of Orthopaedic Surgery, School of Medicine, Fukushima Medical University, 1 Hikariga-oka, Fukushima, 960-1295, Japan, 81 24-547-1276, 81 2…. Major MEDLINE topics: Mobile Applications, Smartphone, Exercise Therapy. Cited 2 times so far (Crossref); 37 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Individuals with locomotive syndrome (LS) have muscle weakness and reduced motor function due to musculoskeletal disorders that cause reduced mobility and physical function. In Japan, musculoskeletal disorders are the most common reason for requiring home support or nursing care, highlighting the need for preventing and ameliorating LS. Middle-aged and older adults sometimes encounter difficulty making a habit of exercise therapy (the mainstay of LS treatment).
Objective
We investigated whether digital therapeutics (DTx) can prevent or ameliorate LS in middle-aged and older adults.
Methods
We conducted a prospective, longitudinal, nonrandomized, single-group study of Japanese aged 40 years and older who were eligible for LS checkups (N=47). Each participant underwent an 8-week locomotion training intervention based on DTx supervised by medical staff. We objectively assessed the participants’ subjective and objective motor abilities and motor awareness with the Timed Up and Go (TUG) test, 25-question Geriatric Locomotive Function Scale (GLFS-25), and Behavioral Regulation in Exercise Questionnaire-3 at baseline (before the DTx), an interim point (4 wk after the DTx initiation), and a final evaluation (8 wk post-DTx initiation). We compared the scores of the 3 tests at the 3 time points as dependent variables in a 3-factor ANOVA with Bonferroni correction (significance defined as 0.05/3=0.0167).
Results
No increase in amotivation to exercise or refusal to exercise was observed. Significant improvements at 8 weeks versus the baseline were observed in the TUG scores (baseline: 9.0, 95% CI 8.4‐9.6; 8 wk: 7.5, 95% CI 7.1‐8.0; P =.001) and GLFS-25 results (baseline: 18.7, 95% CI 14.5‐22.8; 8 wk: 11.7, 95% CI 8.8‐14.7; P =.004). The Behavioral Regulation in Exercise Questionnaire-3 and its subscale data did not differ significantly at any assessment time point.
Conclusions
These results indicate that an 8-week locomotive training intervention using DTx significantly improved middle-aged and older adults’ TUG and GLFS-25 scores and will help prevent and ameliorate LS and establish better exercise habits among them.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Orthopaedic Surgery, School of Medicine, Fukushima Medical University, 1 Hikariga-oka, Fukushima, 960-1295, Japan, 81 24-547-1276, 81 24-548-5505.
- Department of Orthopaedic Surgery, KKR Hamanomachi Hospital, Fukuoka, Japan.
- Future Corporation, Tokyo, Japan.
Cite
APA
Sonobe, T., Ogawa, I., Seki, T., Watanabe, K., Kaneko, Y., Yokota, T., Mawatari, T., Harada, S., Kadowaki, Y., Takenaka, Y., & Matsumoto, Y. (2026). Locomotive Syndrome Digital Therapeutics Provided via a Smartphone App: Proof-of-Concept Single-Group Trial Study. JMIR Aging. https://doi.org/10.2196/86174
Vancouver
Sonobe T, Ogawa I, Seki T, Watanabe K, Kaneko Y, Yokota T, et al. Locomotive Syndrome Digital Therapeutics Provided via a Smartphone App: Proof-of-Concept Single-Group Trial Study. JMIR Aging. 2026. doi:10.2196/86174
BibTeX
@article{Sonobe2026,
author = {Sonobe, Tatsuru and Ogawa, Itaru and Seki, Takahiro and Watanabe, Kosuke and Kaneko, Yota and Yokota, Takeru and Mawatari, Taro and Harada, Satoru and Kadowaki, Yasumichi and Takenaka, Youhei and Matsumoto, Yoshihiro},
title = {Locomotive Syndrome Digital Therapeutics Provided via a Smartphone App: Proof-of-Concept Single-Group Trial Study},
journal = {JMIR Aging},
year = {2026},
doi = {10.2196/86174}
}
EUVIMED